TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04124354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity
Description: Participants will attend 3 treadmill walking sessions/week for 8 weeks (24 total)-exercising at 60-75% of their heart rate (HR) reserve monitored using Polar FT1 HR monitors. All walking sessions will take place using treadmills within the West Bank Office Building on the UMN-Twin Cities campus. Each walking session will be 30 min long during intervention weeks 1-4 and 45 min each during weeks 5-8. This exercise dose is equivalent to that employed in the only two human studies of exercise and the gut microbiome in addition to the dosage observed necessary to yield meaningful cardiometabolic changes. After the 4th- and 8th-weeks of the intervention, participants in both study groups will again undergo outcome assessments
Study: NCT02230267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exercise and balance training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care arm exercise
Study: NCT02011828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: 50,000 IU/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Description: 50,000 IU/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study: NCT04541173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Y-90 TARE
Description: This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Y-90 TARE
Description: This plan will involve treating the predominant liver lesions with segment Y-90 TARE using predetermined dosimetry, while keeping FLR equal or greater than 40% (FLR is estimated by excluding the liver volume of Y-90 infused distribution).~The maximal amount of Y-90 TARE treatment will be limited to only one lobe of the liver if segmental Y-90 TARE is not possible to treat the predominant lesion. Since segmental Y-90 TARE may result in less long term liver damage compared to lobal Y-90 TARE, segmental Y-90 TARE treatment is preferred to lobar Y-90 TARE if segmental Y-90 TARE treatment is able to treat all blood supply to the predominant lesion or lesion with vascular invasion to preserve liver function. For segmental treatment, a minimum tumor dose of 190 Gy should be used for glass microspheres and 120 Gy for resin microspheres. For lobar treatment, a minimum dose of 100 Gy should be used for resin microspheres.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks). The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle.The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 minutes
Study: NCT00695045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra thecal morphine
Description: 100 mcg intrathecal morphine given once .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra thecal morphine
Description: 200 mcg intrathecal morphine given once

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra thecal morphine
Description: 300 mcg intrathecal morphine given once
Study: NCT00845130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ascorbic acid (Vitamin C)
Description: ascorbic acid IV 1 g/kg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ascorbic acid (Vitamin C)
Description: ascorbic acid IV 1 g/kg
Study: NCT01143337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-435(dose1) + Methotrexate
Description: MP-435 dose1 + stable weekly dose of Methotrexate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Methotrexate
Description: Placebo + stable weekly dose of Methotrexate
Study: NCT03086434

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Culturally Tailored Intervention
Description: School-based substance use prevention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Substance Abuse Education
Description: Class room program
Study: NCT00989170

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
Study: NCT03160911

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-scope clip (OTSC)
Description: The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. Endoscopic haemostasis would be achieved with the use of this device and/or injection of adrenaline

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Endoscopic Haemostasis
Description: This includes the use of heater probe, endoscopic clipping and injection of adrenaline for endoscopic haemostasis
Study: NCT00651469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)
Description: The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
Study: NCT04125017

Intervention type: DEVICE
Group type: OTHER
Intervention: ICSI with laser pulse
Description: Using laser pulse before ICSI

Intervention type: DEVICE
Group type: OTHER
Intervention: ICSI with laser pulse
Description: Using laser pulse before ICSI

Intervention type: DEVICE
Group type: OTHER
Intervention: ICSI with micro needle technique
Description: Using micro needle technique before ICSI

Intervention type: DEVICE
Group type: OTHER
Intervention: ICSI with micro needle technique
Description: Using micro needle technique before ICSI
Study: NCT03883685

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotane
Description: probiotics capsules of blended strains including Lactobacillus acidophilus, L. casei and L. rhamnosus
Study: NCT04777552

Intervention type: OTHER
Intervention: diazepam (or equivalence if other benzodiazepine)

Intervention type: OTHER
Intervention: diazepam (or equivalence if other benzodiazepine)
Study: NCT01683773

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: Intramuscular needle injection 1x10\^11 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: Intramuscular needle injection 1x10\^11 vp

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Intradermal needle injection 1x10\^8 pfu

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA85A
Description: Intradermal needle injection 1x10\^8 pfu
Study: NCT01650155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1005273 s.c.
Description: injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 105273 i.v. Placebo
Description: infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BI 1005273 s.c. Placebo
Description: injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1005273 i.v.
Description: infusion
Study: NCT04738968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear implant
Description: A cochlear implant is standard care for profoundly deaf persons. It enables hearing through electrical stimulation of the auditory nerve.
Study: NCT03276767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endre
Description: The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endre
Description: The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt.
Study: NCT03883685

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03492996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCB01-0371 dose with a [14C]-LCB01-0371-tracer dose
Description: To assess the absorption, metabolism, excretion of LCB01-0371 after a single oral LCB01-0371 dose with a \[14C\]-LCB01-0371-tracer dose to healthy subjects
Study: NCT04333264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: suction drainage
Description: After primary total hip arthroplasty closed suction drainage will be used.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: no suction drainage
Description: After primary total hip arthroplasty closed suction drainage won't be used.
Study: NCT01723683

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Surfactant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surfactant
Study: NCT03258957

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Milk
Description: Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
Study: NCT05809154

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-Urodynamics
Description: Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-Urodynamics
Description: Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-Urodynamics
Description: Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.

Intervention type: DIAGNOSTIC_TEST
Intervention: Video-Urodynamics
Description: Minimal invasive Urodynamic examination: Cystomanometry for the assessment of the bladder storage phase and a pressure-flow for the assessment of the voiding phase. By a thin transurethral catheter, body warm fluid is filled in to the bladder and at the same time is the intravesical and abdominal pressure traced with a computer system. The pelvic floor muscle activity is assessed at the same time using EMG surface electrodes.
Study: NCT01931202

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Inert substance or treatment which is designed to have no therapeutic value but resemble the active medication in this study
Study: NCT04124718

Intervention type: GENETIC
Intervention: high caries experience
Description: DNAs were obtained from epithelial cells in buccal mucosa and were extracted with Genomic DNA Isolation Kit
Study: NCT03230929

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS-PLE
Description: Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and adheres the neuromuscular monitoring device on the medial side of the wrist and the ipsilateral thumb to continuously monitor the state of consciousness and muscle relaxation before, during and after surgery. Reversal of muscle relaxant could be performed by intravenous injection of sugammadex 4 mg/ kg in the case of deep neuromuscular relaxation, and 2 mg / kg in the case of shallow muscle relaxation degree under neuromuscular monitoring. After then, they monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring in 1 minute increments for 5 minutes.
Study: NCT03773055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPC-06
Description: Patients will receive once a day for 7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPC-06
Description: Patients will receive once a day for 7 days.
Study: NCT03398408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: The intervention group will be provided with the cognitive training module and participants will be required to complete a targeted 36-minute daily training for 35 days.
Study: NCT04433520

Intervention type: DEVICE
Intervention: Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder
Description: Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer PFO Occluder, ASO or Amplatzer Cribriform Occluder.

Intervention type: DEVICE
Intervention: Amplatzer™ Trevisio™ Intravascular Delivery System using Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder
Description: Amplatzer Trevisio Delivery System is used for facilitating percutaneous, transcatheter implantation of the Amplatzer Muscular VSD Occluder or Amplatzer Post-Infarct Muscular VSD Occluder.
Study: NCT03356847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitting of ocular implant
Description: Removal of natural lens and replacement with a SISA monofocal intraocular implant
Study: NCT02267499

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLM training
Description: Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
Study: NCT02672956

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ten mm trocar

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ten mm trocar

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ten mm trocar
Study: NCT01522651

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Tablets administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Tablets administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine
Description: Tablets administered orally twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Capsule administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Capsule administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Capsule administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranolazine placebo
Description: Tablets administered orally twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ranolazine placebo
Description: Tablets administered orally twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dronedarone placebo
Description: Capsules administered orally twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone placebo
Description: Capsules administered orally twice daily
Study: NCT00754429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan
Description: losartan 50mg qd for 30 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: amlodipine
Description: amlodipine 5 mg q.d for 30 weeks.
Study: NCT04143971

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intermittent fasting diet
Description: intermittent fasting diet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: low calorie diet
Description: continuous low calorie diet
Study: NCT03964415

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.Mos4.HIV
Description: Participants will receive Ad26.Mos4.HIV via IM injection into the deltoid muscle at months 0 (Day 1), 3, 6 and 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clade C and Mosaic gp140 HIV bivalent vaccine
Description: Participants will receive Clade C and Mosaic gp140 HIV bivalent vaccine as IM injection into the deltoid muscle at Months 6 and 12.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo.
Study: NCT03829189

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: prebiotic supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: placebo supplement
Study: NCT00744055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prazosin
Description: prazosin (16mg/day) 2 times a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02144220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual care visit
Description: Video-conferencing visit with a Parkinson disease specialist
Study: NCT01198418

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Internet-based intervention that assesses transmission risk and provides prevention messages
Study: NCT03201653

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stump closure using NU-KNIT SURGICEL
Description: We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stump closure using NU-KNIT SURGICEL
Description: We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
Study: NCT04494009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCMGA00012
Description: INCMGA00012 (also known as MGA012) is a humanized, hinge-stabilized IgG4 monoclonal antibody against human PD-1, which blocks the interaction of PD-1 with PD-L1 and PD-L2, interrupting PD-1 signaling, enhances antigen-induced interferon-γ release, and has a favorable preclinical profile.
Study: NCT01662973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional plus UC-MSC treatment
Description: Received conventional treatment and taken i.v., once per 4 week, at a dose of 1\*10E6 UC-MSC/kg body weight for 12 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional plus placebo treatment
Description: Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
Study: NCT01628991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioural program
Description: interventional behavioural program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iranian version of vaginal cones
Description: intravaginal device(vaginal cone) for promote the pelvic floor exercises
Study: NCT01052012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SABER-Bupivacaine
Description: Injectable Extended Release Solution; SABER-Bupivacaine /Once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Injectable Solution; Bupivacaine HCl /Once

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SABER-Placebo
Description: Injectable Solution; SABER-Placebo/Once
Study: NCT04250493

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Homeostasis Model Assessment of insulin resistance (HOMA)
Description: Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Homeostasis Model Assessment of insulin resistance (HOMA)
Description: Fasting blood sample for : glucose, insulinemia, hemoglobin and lipid test to determine the Homeostasis Model Assessment of insulin resistance (HOMA) index

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MOntreal Cognitive Assessment (MoCA)
Description: Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOntreal Cognitive Assessment (MoCA)
Description: Cognitive evaluation with MOntreal Cognitive Assessment (MoCA)